Efficacy, tolerability and management of raltitrexed (Tomudex™) monotherapy in patients with advanced colorectal cancer

This publication has 14 references indexed in Scilit:

• ‘Tomudex’ (raltitrexed) 4.0 mg/m[2] as second- or third-line therapy in patients with advanced colorectal cancer: a Phase II study
  European Journal Of Cancer, 1999
• Which 5-fluorouracil regimen? — the great debate
  Anti-Cancer Drugs, 1999
• Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694)
  British Journal of Cancer, 1998
• Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number
  European Journal Of Cancer, 1998
• Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
  Journal of Clinical Oncology, 1998
• Metabolism, excretion and pharmacokinetics of a single dose of [ 14 C]-raltitrexed in cancer patients
  Cancer Chemotherapy and Pharmacology, 1998
• Final results of a randomised trial comparing ‘Tomudex’® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
  Annals of Oncology, 1996
• ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer
  European Journal Of Cancer, 1995
• Clinical Pharmacology of 5-Fluorouracil
  Clinical Pharmacokinetics, 1989
• Prediction of Creatinine Clearance from Serum Creatinine
  Nephron, 1976